ReviewBosnian journal of basic medical sciences2017
Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.
Review in Bosnian journal of basic medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07613151 (NAPOLI), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NAPOLI: Negative/Low Hormone Receptor and APOcrine Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study
Who cites it
19 citing papers in PubMed, 57 citations in OpenAlex.
- HER2-positive apocrine carcinoma of the breast and PIK3CA mutations.Breast cancer (Tokyo, Japan) · 2026Article
- Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases.Frontiers in oncology · 2026Article
- Article
- Invasive lobular carcinoma of the breast: metastatic patterns and treatment modalities-a review.Frontiers in oncology · 2025Review
- The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status.Biomolecules & biomedicine · 2024Article
- A Preliminary Investigation into Search and Matching for Tumor Discrimination in World Health Organization Breast Taxonomy Using Deep Networks.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Article
- Article
- Pregnancy Associated Invasive Apocrine Carcinoma of the Breast: Case Report from Ethiopia.Breast cancer (Dove Medical Press) · 2023Article
- Multiomic analysis of HER2-enriched and AR-positive breast carcinoma with apocrine differentiation and an oligometastatic course: a case report.Frontiers in oncology · 2023Article
- Article
- HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.Breast cancer research and treatment · 2022Article
- Apocrine lesions of the breast.Virchows Archiv : an international journal of pathology · 2022Review
- Breast Apocrine Carcinoma Detected Incidentally as Axillary Lymphadenopathy in a CT Scan.Cureus · 2021Article
- Histology of Luminal Breast Cancer.Breast care (Basel, Switzerland) · 2020Review
- Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.BMC cancer · 2020Observational
- Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.Cancers · 2020Review
- Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.Cancer medicine · 2019Article
- Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.Bosnian journal of basic medical sciences · 2019Review
- Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apocrine carcinoma of the breast is a rare, primary breast cancer characterized by the apocrine morphology, estrogen receptor-negative and androgen receptor-positive profile with a frequent overexpression of Her-2/neu protein (~30%). Apart from the Her-2/neu target, advanced and/or metastatic apocrine carcinomas have limited treatment options. In this review, we briefly describe and discuss the molecular features and new theranostic biomarkers for this rare mammary malignancy. The importance of comprehensive profiling is highlighted due to synergistic and potentially antagonistic molecular events in the individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.